MD Anderson implements proactive measures due to 2019 novel coronavirus disease (COVID-19)
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout the 2019 novel coronavirus disease (COVID-19) pandemic. As part of our commitment, the institution is taking additional proactive measures to prevent the introduction or spread of COVID-19 at any of our campuses.
MD Anderson is:
Requiring quarantine for new patients traveling from...
New therapeutic strategies proposed for some lung and kidney cancers
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to glucose...
Combination creates powerful central memory T cells for cellular therapy
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...
Study sheds light on fatty acid’s role in “chemobrain” and multiple sclerosis
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The University of Texas MD Anderson Cancer Center has found that myelin is surprisingly dynamic, a discovery that has implications for treatment of multiple sclerosis and a type of myelin damage caused by some chemotherapy drugs, often referred to as “chemobrain.” Chemobrain can occur in up to 70 percent of patients...
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity...
MD Anderson returning to normal operations on Monday, March 2
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after operating...